Skip to search formSkip to main contentSkip to account menu

EMD 72000

Known as: EMD-72000, EMD72000 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

matuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
MR Signal Amplification for Imaging of the Mutant EGF Receptor in Orthotopic Human Glioma Model
PurposeTo investigate the potential of targeted MR signal amplification strategy for imaging of EGF receptor variant III… 
2011
2011
MR Imaging of U 87 Δ EGFR Human Glioma Tumor Xenografts Using Targeted Signal-Amplifying Enzymatic System
Introduction: A truncated and constitutively active form of the EGF receptor variant III (EGFRvIII) is a major determinant of… 
2006
2006
Signifikante EGF Rezeptor Inhibition und anhaltende antineoplastische Wirkung durch Matuzumab Kurzzeittherapie (EMD72000) im experimentellen Pankreaskarzinom Matuzumab short term therapy (EMD72000…
Pancreatic cancer continues to be a major unsolved health problem with a median overall survival of 4-6 month. Standard… 
Review
2005
Review
2005
Monoclonal antibodies targeting the epidermal growth factor receptor.
The epidermal growth factor receptor (EGFR, HER1) autocrine pathway contributes to a number of highly relevant processes in… 
2005
2005
Magnetic resonance imaging in an orthotopic rat model: Blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth
The purpose of our research was to investigate the antiangiogenic effect of the epidermal growth factor receptor monoclonal… 
2005
2005
A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Mullerian malignancies
3151 Background: A high proportion of ovarian tumors express the epidermal growth factor receptor (EGFR). Preclinical and… 
2005
2005
A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK…
3077 Background: Matuzumab is a humanized monoclonal antibody binding to the EGFR with higher affinity than natural ligands (eg… 
2004
2004
Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer.
3061 Background: Monoclonal antibody EMD 72000 blocks ligand binding and inhibits EGFR activation and signal transduction. EGFR… 
2004
2004
Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC).
3043 Background: EGFR is a potential therapeutic target in HNSCC. EGFR signaling inhibitors such as EMD 72000, a humanized anti… 
2003
2003
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)